Page last updated: 2024-10-20

trimethylamine and 2019 Novel Coronavirus Disease

trimethylamine has been researched along with 2019 Novel Coronavirus Disease in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Chiang, EI1
Syu, JN1
Hung, HC1
Rodriguez, RL1
Wang, WJ1
Chiang, ER1
Chiu, SC1
Chao, CY1
Tang, FY1
Alexander, JL1
Mullish, BH1
Danckert, NP1
Liu, Z1
Olbei, ML1
Saifuddin, A1
Torkizadeh, M1
Ibraheim, H1
Blanco, JM1
Roberts, LA1
Bewshea, CM1
Nice, R1
Lin, S1
Prabhudev, H1
Sands, C1
Horneffer-van der Sluis, V1
Lewis, M1
Sebastian, S1
Lees, CW1
Teare, JP1
Hart, A1
Goodhand, JR1
Kennedy, NA1
Korcsmaros, T1
Marchesi, JR1
Ahmad, T1
Powell, N1

Other Studies

2 other studies available for trimethylamine and 2019 Novel Coronavirus Disease

ArticleYear
N-3 polyunsaturated fatty acids block the trimethylamine-N-oxide- ACE2- TMPRSS2 cascade to inhibit the infection of human endothelial progenitor cells by SARS-CoV-2.
    The Journal of nutritional biochemistry, 2022, Volume: 109

    Topics: Angiotensin-Converting Enzyme 2; COVID-19; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelial

2022
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
    EBioMedicine, 2023, Volume: 88

    Topics: Antibody Formation; BNT162 Vaccine; ChAdOx1 nCoV-19; COVID-19; COVID-19 Vaccines; Gastrointestinal M

2023